Risk-Benefit Analysis of Vascular Rejuvenation using EDTA
The Forever Healthy Foundation announces the launch of the “Vascular Rejuvenation using EDTA” Risk-Benefit Analysis.
The team evaluates the use of EDTA chelation therapy and its rejuvenating effects on the cardiovascular system. Potential benefits include stabilization and reduction of atherosclerotic plaque, prevention of epigenetic changes, stabilization of membranes, and a substantial reduction of adverse cardiovascular events such as heart attack and stroke.
Over 2100 scientific papers were screened, followed by an in-depth analysis of the most relevant clinical trials to determine the usefulness and optimal application of this amazing therapeutical approach to rejuvenating the cardiovascular system.
It is the fourth publication of Forever Healthy’s “Rejuvenation Now” initiative following NAD+ Restoration Therapy, Fisetin as a Senolytic and Skin Rejuvenation by Low-Level Light Therapy.
About the “Rejuvenation Now“ Initiative:
Senolytics, NAD+, Lipid Replacement, Decalcification, mTOR Inhibitors, Geroprotectors, … – the first generation of human rejuvenation therapies is available today. However, the field is still very young and the information often spotty. New therapies are emerging, and existing ones are updated or replaced presenting a real challenge for those who want to take advantage of this exciting development as soon as possible.
To overcome this, Forever Healthy’s “Rejuvenation Now” initiative seeks to continuously identify rejuvenation therapies that are available right now and systematically evaluates them on their risks, benefits, procedures and potential application in order to create transparency regarding the current state of said therapies.
Upcoming work of the initiative will cover topics such as Dasatinib Senolytic Therapy
Coverage at Undoing Aging 2020:
For a first, the Undoing Aging conference in 2020 will feature a special “Rejuvenation Now” session highlighting the first generation of human rejuvenation therapies that are either currently in clinical trials or are available today – including risk mitigation strategies and practical application.